Drugs / 3D1002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05265052 | Dec 2026 expected | — | 3D Medicines | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3D1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05265052 ↗ |
| Action | Inhibit | “3D1002, is a selective antagonist of prostaglandin E2 receptor subtype 4 (EP4)” NCT05265052 ↗ |
| Route | Oral | “1 tablet of 3D1002 per oral dose” NCT05265052 ↗ |